RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1757422
Real-World Evaluation of Response to Hepatitis B Vaccination in Cirrhosis: A Brief Report
Funding None.
Abstract
Information regarding seroresponse to hepatitis B virus (HBV) vaccination in India is sparse. We aimed to determine response rates to HBV vaccination in adult cirrhotic patients. We included adult patients (> 18 years) with cirrhosis after screening for hepatitis B surface antigen (HBsAg), anti-HBc, and anti-HBs. Those who were seronegative were advised vaccination. We excluded patients who were known HBsAg positive, on oral antiviral drugs, who did not complete the recommended vaccination regimen, and those who were lost to follow-up. Two months after completion of vaccination, anti-HBs titers were measured. Titers more than10 IU/L were considered as response, while less than 10 IU/L was labeled as nonresponse. The two groups were compared for baseline demographic parameters, anthropometry, model of end-stage liver disease score, and history of prior vaccination. The study cohort included 164 patients (median age: 43, range: 18–68 years, and 67% males). On follow-up at 2 months after vaccination, 103 (62.8%) patients had anti-HBs titer more than 10 IU/L. Of these, 54 (52.4%) had titers more than 100 and 49 (47.6%) had titers ranging from 10 to 99. Nonresponders were significantly older than responders (48 vs. 41 years, p = 0.01). Seroresponse to HBV vaccination in adult patients with cirrhosis was 62.8%. Older age predicted nonresponse to HBV vaccination.
Ethical Statement
Written informed consent was obtained from the patients. Ethical Clearance was obtained from Ethics committee, Arihant Hospital and Research Centre, Indore, India.
Author Contributions
M.J. conceptualised, collected data, analyses, wrote the draft and approved the work.
Data Availability statement
The corresponding author will provide anonymized data on a reasonable request.
Publikationsverlauf
Eingereicht: 16. Mai 2022
Angenommen: 06. Juni 2022
Artikel online veröffentlicht:
22. September 2023
© 2023. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Van Thiel DH. Vaccination of patients with liver disease: who, when, and how. Liver Transpl Surg 1998; 4 (02) 185-187
- 2 Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver Transpl Surg 1998; 4 (05) 437-439
- 3 Trantham L, Kurosky SK, Zhang D, Johnson KD. Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States. Vaccine 2018; 36 (35) 5333-5339
- 4 Mukhtar NA, Kathpalia P, Hilton JF. et al. Provider, patient, and practice factors shape hepatitis B prevention and management by primary care providers. J Clin Gastroenterol 2017; 51 (07) 626-631
- 5 Bonazzi PR, Bacchella T, Freitas AC. et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis 2008; 12 (04) 306-309
- 6 Yang S, Tian G, Cui Y. et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep 2016; 6: 27251
- 7 Joshi SS, Davis RP, Ma MM. et al. Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines 2021; 6 (01) 9
- 8 Ashhab AA, Rodin H, Campos M. et al. Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection. PLoS One 2020; 15 (08) e0237398
- 9 Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol 2013; 2013: 196704
- 10 Wilson JN, Nokes DJ. Do we need 3 doses of hepatitis B vaccine?. Vaccine 1999; 17 (20-21): 2667-2673
- 11 Rambusch EG, Nashan B, Tillmann HL. et al. [De novo hepatitis B infection after liver transplantation–evidence for the need of active hepatitis B vaccination of liver transplantation candidates]. Z Gastroenterol 1998; 36 (12) 1027-1035
- 12 Lin CC, Yong CC, Chen CL. Active vaccination to prevent de novo hepatitis B virus infection in liver transplantation. World J Gastroenterol 2015; 21 (39) 11112-11117